The study, led by the University of Leeds and Mount Sinai Hospital in Toronto, is published today in the journal Neuropsychopharmacology. It sheds light on the molecular underpinnings of learning and memory and could form the basis for research into new treatments for age-related cognitive decline, cognitive disorders such as Alzheimer’s disease and schizophrenia, and other conditions.
The researchers altered a gene in mice to inhibit the activity of an enzyme called phosphodiesterase-4B (PDE4B), which is present in many organs of the vertebrate body, including the brain.
In behavioural tests, the PDE4B-inhibited mice showed enhanced cognitive abilities.
They tended to learn faster, remember events longer and solve complex exercises better than ordinary mice.
For example, the “brainy mice” showed a better ability than ordinary mice to recognise another mouse that they had been introduced to the day before. They were also quicker at learning the location of a hidden escape platform in a test called the Morris water maze.
However, the PDE4B-inhibited mice also showed less recall of a fearful event after several days than ordinary mice.
The published findings are limited to mice and have not been tested in humans, but PDE4B is present in humans. The diminished memory of fear among mice with inhibited PDE4B could be of interest to researchers looking for treatments for pathological fear, typified by Post-Traumatic Stress Disorder (PTSD)
The PDE4B-inhibited mice also showed less anxiety. They spent more time in open, brightly-lit spaces than ordinary mice, which preferred dark, enclosed spaces.
Ordinary mice are naturally fearful of cats, but the PDE4B-inhibited mice showed a decreased fear response to cat urine, suggesting that one effect of inhibiting PDE4B could be an increase in risk-taking behaviour.
So, while the PDE4B-inhibited mice excelled at solving complex exercises, their low levels of anxiety could be counterproductive for a wild mouse.
Dr Steve Clapcote, Lecturer in Pharmacology in the University of Leeds’ School of Biomedical Sciences, led the study. He said: “Cognitive impairments are currently poorly treated, so I’m excited that our work using mice has identified phosphodiesterase-4B as a promising target for potential new treatments”.
The researchers are now working on developing drugs that will specifically inhibit PDE4B. These drugs will be tested in animals to see whether any would be suitable for clinical trials in humans.
Dr Alexander McGirr, a psychiatrist in training at the University of British Columbia, who co-led the study, said: ""In the future, medicines targeting PDE4B may potentially improve the lives of individuals with neurocognitive disorders and life-impairing anxiety, and they may have a time-limited role after traumatic events.”
Dr Laura Phipps of Alzheimer’s Research UK, who were not involved in the study, said:
“This study highlights a potentially important role for the PDE4B gene in learning and memory in mice, but further studies will be needed to know whether the findings could have implications for Alzheimer’s disease or other dementias. We’d need to see how this gene could influence memory and thinking in people to get a better idea of whether it could hold potential as a target to treat Alzheimer’s.
“There is currently a lack of effective treatments for dementia and understanding the effect of genes can be a key early step on the road to developing new drugs. With so many people affected by dementia, it is important that there is research into a wide array of treatment approaches to have the best chance of helping people sooner.”
The study involved researchers from Leeds, Mount Sinai Hospital, University of British Columbia, the University of Toronto, the National Genetic Centre in Oman, the Centre for Addiction and Mental Health in Toronto, the University of Glasgow and Swansea University. The study was funded by the UK Medical Research Council.
Dr Clapcote is available for interview.
Contact: University of Leeds press office on 0113 343 2049 or email firstname.lastname@example.org
The full paper: McGirr A, Lipina TV, Mun H-S, Georgiou J, Al-Amri AH, Ng E, Zhai D, Elliott C, Cameron RT, Mullins JGL, Liu F, Baillie GS, Clapcote SJ, Roder JC. (2015). ‘Specific inhibition of phosphodiesterase-4B results in anxiolysis and facilitates memory acquisition.’ is published in Neuropsychopharmacology
The paper is available on request.
Ralf Richter, David Brockwell, Eric Hewitt, Jessica Kwok, Emanuele Paci and MAPS/FMH, BBSRC (Jun 2017), £600,000
Eric Blair, Adrian Whitehouse, Nicola Stonehouse, Alison Baker, Richard Bayliss, Joan Boyes, Ryan Seipke, Sally Boxall and MAPS/FMH, BBSRC (Jun 2017), £376,000
Stefan Kepinski, Yoselin Benitez-Alfonso, Tom Bennett, Michelle Peckham, BBSRC (Jun 2017), £331,000
Roman Tuma, Lars Jeuken, Paul Millner, Sheena Radford, Peter Stockley and MAPS/FMH, BBSRC (Jun 2017), £222,000
Vas Ponnambalam, Darren Tomlinson, Stephen Wheatcroft, BHF (May 2017), £107,878
Graham Askew in collaboration with Bangor University, BBSRC (Mar 2017), £477,383
Stephen Muench, BBSRC (Mar 2017), £132,945
Nic Stonehouse, MRC (Mar 2017), £906,341
Bill Kunin, Steve Sait, BBSRC (Mar 2017), £602,831
Adrian Goldman, EU (Mar 2017), £546,576
Sheena Radford, Wellcome Trust (Mar 2017), £1,836,482
Beatrice Filippi, Royal Society (Mar 2017), £15,000
Jamie Johnston, Royal Society (Mar 2017), £15,000
Tom Bennett, Royal Society (Mar 2017), £15,000
Ryan Seipke, BBSRC (Feb 2017), £52,116
Mary O'Connell, BBSRC (Feb 2017), £46,986
Hannah Dugdale, NERC (Feb 2017), £504,138
Anastasia Zhuravleva, EPSRC (Jan 2017), £100,792
Richard Bayliss, Cancer Research UK (Jan 2017), £1,600,000
John Barr, EU (Jan 2017), £339,000
Mark Harris, Royal Society (Jan 2017), £250,000
Alison Dunn, NERC (Jan 2017), £105,000
Alex Breeze, Pancreatic Cancer Research Fund (Jan 2017), £180,000
Alison Dunn, NERC (Dec 2016), £18,000
Lisa Collins, BBSRC (Dec 2016), £1,681,835
Brendan Davies, Leverhulme Trust (Dec 2016), £247,555
Alan Benson, Mark Drinkhill, Ed White, British Heart Foundaion (Dec 2016), £217,223
Adrian Goldman, Royal Society (Dec 2016), £82,999
Lisa Roberts, Alex Breeze, Brendan Davies, Timothy Devinney, Oliver Harlen, Joseph Holden, Anthea Hucklesby, Pamela Jones, Philip Mellor, RCUK (Nov 2016), £484,172
Lisa Roberts, Alex Breeze, Brendan Davies, Timothy Devinney, Oliver Harlen, Joseph Holden, Anthea Hucklesby, Pamela Jones, Philip Mellor, Wellcome Trust (Nov 2016), £119,343
Katie Field, Rank Prize Funds (Nov 2016), £20,000
Jessica Kwok, Royal Society (Nov 2016), £14,948
John Ladbury, Cancer Research UK (Oct 2016), £4,250
Miriam Wittmann, Martin Stacey, Edward Vital, Lupus UK
(Oct 2016), £34,010
Valerie Speirs, NC3Rs
(Oct 2016), £90,000
Nicola Stonehouse, Morgan Herod, David Rowlands, BBSRC
(Sep 2016), £436,424
Joseph Cockburn, Wellcome Trust
(Sep 2016), £100,000
John Barr, Public Health England
(Sep 2016), £94,471
Helen Miller, DSM Nutritional Products A/S
(Sep 2016), £54,680
Steven Clapcote, Vitaflo International Ltd
(Sep 2016), £39,285
Juan Fontana Jordan De Urries
, Royal Society
(Sep 2016), £21,793
Jing Li, Sarah Calaghan, Mark Drinkhill, British Heart Foundation
(Sep 2016), £117,585
Sheena Radford, Alison Ashcroft, BBSRC (Sep 2016), £457,216
Patricija Van Oosten-Hawle, An-Jung Chen, David Westhead, NC3Rs
(Sep 2016), £354,456
Glyn Hemsworth, BBSRC (Sep 2016), £1,024,034
David Jayne, Paul Millner, MRC (Aug 2016), £207,860
Sheena Radford, Alison Ashcroft, BBSRC (Aug 2016), £457,215
Patricija Van Oosten-Hawle, Dave Westhead, An-Jung Chen, NC3Rs (Aug 2016), £354,456
Peter Henderson, EU - European Union
EU - European Union
(Jul 2016), £123,897
Adrian Goldman, EU - European Union
(Jul 2016), £116,290
Urwin, Howard Atkinson, NERC
(Jul 2016), £105,053
Eileen Ingham and colleagues in Engineering and M&H, EPSRC (Jul 2016), £3,867,449
Michael Colman, MRC (Jul 2016), £200,956
Tim Benton, Fresca Group Ltd
(Jul 2016), £52,082
Derek Steele, Sarah Calaghan, Chris Peers, BHF (Jul 2016), £819,241
Paul Millner and colleagues in Engineering and M&H, BBSRC (Jul 2016), £129,647
Vas Ponnambalam, Darren Tomlinson, Stephen Wheatcroft, BHF (Jul 2016), £107,359
John Colyer, Christian Teade and colleagues in M&H, Kidney Research Fund UK (Jul 2016), £39,964
Nicola Stonehouse, David Rowlands, World Health Organisation (Jul 2016), £656,545
Alexander Breeze, MRC
(Jul 2016), £403,513
Yoselin Benitez-Alfonso and colleagues in MaPS, Leverhulme Trust (Jul 2016), £353,301
Joan Boyes, Peter Stockley, Roman Tuma, David Westhead, Bloodwise (Jul 2016), £232,960
Edwin Chen, Leuka
(Jul 2016), £98,642
Helen Miller, Hamlet Protein A/S
(Jul 2016), £22,240
Alexander Breeze, Syngenta
(Jul 2016), £299,629
Alan Berry, Wellcome Trust
(Jul 2016), £599,375
Amanda Bretman, Elizabeth Duncan, Leverhulme Trust
(Jul 2016), £245,369
Andrew Macdonald, Neil Ranson, Richard Foster, Yorkshire Kidney Research Fund (Jul 2016), £51,368
Roman Tuma, Sheena Radford, BBSRC
(Jul 2016), £379,786
Adrian Whitehouse, Ian Carr, Worldwide Cancer Research (Jul 2016), £199,738
Paul Milner, Mike McPherson, Lars Jeuken, Darren Tomlinson and colleagues in Engineering & M&H, MRC (Jul 2016), £3,124,568
Helen Miller, Innovate UK (Jun 2016), £3,463,470
Adrian Goldman, Royal Society
(Jun 2016), £250,000
Jim Deuchars, Susan Deuchars, Shaunna Burke, Dunhill Medical Trust (Jun 2016), £86,570